



**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
 (Use several sheets if necessary)

Sheet 1 of 9

ATTORNEY DOCKET NO.	SERIAL NO.
6102-000009/US/NP	10/565699
APPLICANT	
D. Scheller <i>et al.</i>	
FILING DATE	GROUP
January 25, 2006	1617

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
R1		4,320,148	Mar 16, 1982	DeMarinis	424/330	Nov 24, 1980
R2		4,410,519	Oct 18, 1983	Seiler	424/226	Mar 12, 1981
R3		4,501,890	Feb 26, 1985	Nichols <i>et al.</i>	514/267	Sep 26, 1983
R4		4,542,135	Sep 17, 1985	Kobel <i>et al.</i>	514/250	Aug 03, 1982
R5		4,556,676	Dec 03, 1985	Welch <i>et al.</i>	514/554	Sep 05, 1980
R6		4,824,860	Apr 25, 1989	Owen	514/418	May 19, 1988
R7		4,863,951	Sep 05, 1989	Peglion <i>et al.</i>	514/422	Mar 25, 1988
R8		4,863,970	Sep 05, 1989	Patel <i>et al.</i>	514/784	Jul 13, 1988
R9		4,874,768	Oct 17, 1989	Huth <i>et al.</i>	514/288	Oct 06, 1986
R10		4,885,308	Dec 05, 1989	Horn	514/438	Jun 13, 1988
R11		4,996,226	Feb 26, 1991	Horn	514/438	Sep 26, 1989
R12		5,071,875	Dec 10, 1991	Horn	514/613	Sep 25, 1989
R13		5,151,446	Sep 29, 1992	Horn <i>et al.</i>	514/617	Mar 28, 1991
R14		5,214,156	May 25, 1993	Andersson <i>et al.</i>	549/75	Apr 10, 1992
R15		5,462,947	Oct 31, 1995	Svensson <i>et al.</i>	514/317	Oct 12, 1993
R16		5,486,611	Jan 23, 1996	Lin <i>et al.</i>	546/62	Oct 28, 1993
R17		5,496,843	Mar 05, 1996	Nagata <i>et al.</i>	514/411	Nov 14, 1994
R18		5,545,755	Aug 13, 1996	Lin <i>et al.</i>	564/428	Jan 18, 1995
R19		5,614,518	Mar 25, 1997	Leeson <i>et al.</i>	514/234.5	Nov 21, 1994
R20		5,633,376	May 27, 1997	Thurkauf <i>et al.</i>	544/360	Sep 27, 1994
R21		5,656,286	Aug 12, 1997	Miranda <i>et al.</i>	424/449	Jan 07, 1994
R22		5,658,955	Aug 19, 1997	Hitzig	514/654	Nov 01, 1995
R23		5,663,167	Sep 02, 1997	Pickar <i>et al.</i>	514/225.8	Jun 07, 1995
R24		5,681,956	Oct 28, 1997	Thurkauf <i>et al.</i>	544/295	Mar 09, 1995
R25		5,807,855	Sep 15, 1998	Bogeso <i>et al.</i>	514/449	Oct 28, 1994
R26		5,891,891	Apr 06, 1999	Benincasa	514/300	Apr 02, 1996
R27		5,902,603	May 11, 1999	Chen <i>et al.</i>	424/449	Sep 13, 1996
R28		5,906,830	May 25, 1999	Farinas <i>et al.</i>	424/448	Sep 04, 1996

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 2 of 9

ATTORNEY DOCKET NO.	SERIAL NO.
6102-000009/US/NP	10/565699
APPLICANT	
D. Scheller <i>et al.</i>	
FILING DATE	GROUP
January 25, 2006	1617

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
R29		6,001,861	Dec 14, 1999	Oertel <i>et al.</i>	514/367	Jan 16, 1998
R30		6,010,877	Jan 04, 2000	Sathe <i>et al.</i>	435/69.1	Jan 10, 1997
R31		6,024,976	Feb 15, 2000	Miranda <i>et al.</i>	424/449	Aug 11, 1997
R32		6,107,318	Aug 22, 2000	Pocciani <i>et al.</i>	514/366	Jun 12, 1998
R33		6,221,627	Apr 24, 2001	Sathe <i>et al.</i>	435/69.1	Feb 24, 1997
R34		6,300,365	Oct 09, 2001	Holman	514/418	May 07, 2001
R35		6,331,636	Dec 18, 2001	Romero <i>et al.</i>	548/235	Mar 22, 1992
R36		6,465,004	Oct 15, 2002	Rossi-Montero <i>et al.</i>	424/448	Jun 05, 2000
R37		7,038,085	May 02, 2006	Rariy <i>et al.</i>	564/165	Oct 22, 2003
R38		2003/026830	Feb 06, 2003	Lauterbach <i>et al.</i>	424/449	May 07, 2002
R39		2004/0048779	Mar 11, 2004	Schollmayer <i>et al.</i>	514/2	May 02, 2003
R40		2005/0032873	Feb 10, 2005	Hatzenbuhler <i>et al.</i>	514/414	Jul 26, 2004
R41		2005/0033065	Feb 10, 2005	Mueller <i>et al.</i>	549/449	Sep 07, 2004
R42		2005/0107397	May 19, 2005	Galambos <i>et al.</i>	514/255.03	Sep 25, 2002
R43		2005/0182090	Aug 18, 2005	Mierau <i>et al.</i>	514/304	Jan 21, 2005
R44		2005/0197385	Sep 08, 2005	Scheller <i>et al.</i>	514/438	Feb 17, 2005
R45		2005/0260577	Nov 24, 2005	Double <i>et al.</i>	435/6	Oct 09, 2001
R46		2006/0263419	Nov 23, 2006	Wolff	424/448	Sep 29, 2005

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/ Subclass	Translation Yes	Translation No
R301		CA 2532804	Feb 03, 2005	CA	A61K		
R302		CA 2532859	Feb 03, 2005	CA	A61K		
R303		CA 2547820	Jun 30, 2005	CA	A61K		
R304		DE 4325855	Feb 02, 1995	Germany	C07D	X	
R305		WO 93/00313	Jan 07, 1993	PCT	A61K		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
 (Use several sheets if necessary)

Sheet 3 of 9

ATTORNEY DOCKET NO.	SERIAL NO.
6102-000009/US/NP	10/565699
APPLICANT	
D. Scheller <i>et al.</i>	
FILING DATE	GROUP
January 25, 2006	1617

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/ Subclass	Translation Yes	Translation No
R306		WO 93/16073	Aug 19, 1993	PCT	C07D		
R307		WO 94/21244	Sep 29, 1994	PCT	A61K		
R308		WO 94/26703	Nov 24, 1994	PCT	C07C		
R309		WO 95/18603	Jul 13, 1995	PCT	A61K		
R310		WO 96/31210	Oct 10, 1996	PCT	A61K		
R311		WO 97/09971	Mar 20, 1997	PCT	A61K		
R312		WO 97/29735	Aug 21, 1997	PCT	A61K		
R313		WO 99/15210	Apr 01, 1999	PCT	A61K		
R314		WO 99/49852	Oct 07, 1999	PCT	A61K	X	
R315		WO 00/02053	Jun 13, 2000	PCT	GO1N		
R316		WO 00/35954	Jun 22, 2000	PCT	C07K		
R317		WO 00/37426	Jun 29, 2000	PCT	C07C		
R318		WO 00/37438	Jun 29, 2000	PCT	C07C		
R319		WO 01/39756	Jun 07, 2001	PCT	A61K		
R320		WO 01/62249	Aug 30, 2001	PCT	A61K		
R321		WO 01/81343	Nov 01, 2001	PCT	C07D		
R322		WO 02/15903	Feb 28, 2002	PCT	A61K	X	
R323		WO 02/38646	May 16, 2002	PCT	C08G	X	
R324		WO 02/89777	Nov 14, 2002	PCT	A61K		
R325		WO 02/89778	Nov 14, 2002	PCT	A61K		
R326		WO 02/98367	Dec 12, 2002	PCT	A61K		
R327		WO 03/29233	Apr 10, 2003	PCT	C07D		
R328		WO 03/88958	Oct 30, 2003	PCT	A61K		
R329		WO 04/39320	May 13, 2004	PCT	A61K		
R330		WO 04/58247	Jul 15, 2004	PCT	A61K	X	
R331		WO 05/063238	Jul 14, 2005	PCT	A61K	X	

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 4 of 9

ATTORNEY DOCKET No.	SERIAL No.
6102-000009/US/NP	10/565699
APPLICANT	
D. Scheller <i>et al.</i>	
FILING DATE	GROUP
January 25, 2006	1617

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/ Subclass	Translation Yes	Translation No
R332		WO 05/070428	Aug 04, 2005	PCT	A61K		
R333		WO 2006/15737	Feb 16, 2006	PCT	C07D	X	
R334		WO 2006/39532	Apr 13, 2006	PCT	A61K		
R335		WO 2006/50976	Mar 18, 2006	PCT	C07D	X	
R336		WO 06/069030	Jun 29, 2006	PCT	A61K		

**OTHER DOCUMENTS**

Ref. Desig.	Examiner's Initials	
R501		AADAC (2004) Beyond the ABCs: Amphetamines (from <a href="http://www.aadac.com">www.aadac.com</a> ), 5pp
R502		Arnt (1984) <i>Pol. J. Pharmacol. Pharm.</i> 36, 221-230
R503		Balsam <i>et al.</i> (1982) <i>Ind. J. Physiol. Pharmac.</i> 26(3), 183-195
R504		Barfknecht <i>et al.</i> (1973) <i>J. Medicinal Chemistry</i> 16(7), 804-805
R505		Bartoszyk (1998) <i>Life Sciences</i> 62(7), 649-663
R506		Becker <i>et al.</i> (2002) <i>J. Neurol.</i> 249(Suppl. 3), III/40-III/48
R507		Bell (1977) <i>Br. J. Pharm.</i> 61, 291-295
R508		Bijak (1988) <i>Eur. J. Pharmacol.</i> 149, 41-47
R509		Bischoff <i>et al.</i> (1986) <i>Satellite Symp. IUPHAR 9th Int. Congr. Pharmacol. "Dopaminergic Systems and their Regulation"</i> , 397-398
R510		Borsini (1988) <i>Eur. J. Pharmacol.</i> 148, 301-307
R511		Bunney <i>et al.</i> (1982) <i>Pharmacopsychiatry</i> 15, 111-115
R512		Caliendo <i>et al.</i> (2005) <i>Current Medicinal Chemistry</i> 12, 171-173
R513		Camicioli (2002) <i>Drugs of Today</i> 38(10), 677-686
R514		Carp <i>et al.</i> (1982) <i>Brain Research</i> 242, 247-254
R515		Chandler <i>et al.</i> (1990) <i>Neuroscience</i> 38(2), 437-445
R516		Chaudhuri (2002) <i>Eur. J. Neurol.</i> 9(3), 40-43
R517		Chioldo <i>et al.</i> (1980) <i>Eur. J. Pharmacol.</i> 64, 203-204

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
 (Use several sheets if necessary)

Sheet 5 of 9

ATTORNEY DOCKET NO.	SERIAL NO.
6102-000009/US/NP	10/565699
APPLICANT	
D. Scheller <i>et al.</i>	
FILING DATE	GROUP
January 25, 2006	1617

**OTHER DOCUMENTS**

Ref. Desig.	Examiner's Initials	
R518		Christie <i>et al.</i> (1982) Brit. J. Psychiatry 140, 268-273
R519		Collado-Seidel <i>et al.</i> (1999) CNS Drugs Jul 12(1), 9-20
R520		Corsini <i>et al.</i> (1981) Biological Psychiatry, 742-745
R521		Dawson <i>et al.</i> (2002) Nature Neuroscience Supplement 5, 1058-1061
R522		De Boer <i>et al.</i> (1988) Neuropharmacology 27(4), 399-408
R523		De Ceballos <i>et al.</i> (1985) Eur. J. Pharmacology 116, 257-262
R524		Deakin (2002) Internat'l. Clinical Psychopharm. 17(Suppl. 1), S13-S24
R525		den Daas <i>et al.</i> (1990) (Naunyn-Schmiëdeberg's Arch. Pharmacol. 342, 655
R526		den Daas <i>et al.</i> (1991) J. Pharm. Pharmacol. 43, 11
R527		DeNinno <i>et al.</i> (2001) J. Organic Chemistry 66, 6988-6993
R528		Diggory <i>et al.</i> (1984) Eur. J. Pharmacol. 105, 257-263
R529		Doggett (1973) Neuropharmacology 12, 213-220
R530		Domino <i>et al.</i> (1993) J. Pharmacol. Exp. Ther. 264(1), 221-225
R531		Duterte-Boucher <i>et al.</i> (1988) Eur. J. Pharmacol. 154, 185-190
R532		Errico <i>et al.</i> (2001) Neuroscience 102(2), 361-367
R533		Estrada-Camerena <i>et al.</i> (2006) Neuropsychopharmacology 31, 247-255
R534		Faedda <i>et al.</i> (1989) Biochemical Pharmacology 38(3), 473-480
R535		Fajardo <i>et al.</i> (2003) International Immunopharm. 3, 1345-1352
R536		Foley <i>et al.</i> (2004) J. Neural Transmission 111, 1375-1446
R537		Friedman <i>et al.</i> (2004) Parkinsonism and Related Disorders 10, S27-S35
R538		Gerlach <i>et al.</i> (2003) J. Neural Transm. 65(Suppl.), 167-183
R539		Goodwin <i>et al.</i> (1987) Psychopharmacology 91, 500-505
R540		Gorman (1999) Psychiatry 60(Suppl.), 17
R541		Graeff <i>et al.</i> (1971) Arch. Int. Pharmacodyn. 193, 134-148
R542		Green <i>et al.</i> (1983) Br. J. Pharmacol. 80, 377-385
R543		Grippo <i>et al.</i> (2005) Psychopharmacology 179, 769-780

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

FORM HDP-1449 (Based on Form PTO-1449) <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 6 of 9	ATTORNEY DOCKET No.	SERIAL NO.
	6102-000009/US/NP	10/565699
	APPLICANT	
	D. Scheller <i>et al.</i>	
	FILING DATE	GROUP
January 25, 2006		
1617		

### OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
R544		Guttmann (2003) Can. Med. Assoc. J. 168(3), 293-301
R545		Gyure <i>et al.</i> (1985) Proc. 4th Congress Hungary Pharmacol. Soc. Budapest Vol. 2, 309-312
R546		Haddjeri <i>et al.</i> (1999) Biol. Psychiatry 45, 1163-1169
R547		Happe (2004) CNS Drugs 18(1), 27-36
R548		Hauser <i>et al.</i> (2004) Neurol. Clin. 22, S149-S166
R549		Henderson (2003) J. Neurol. Neurosurg. Psychiatry 74, 956-958
R550		Hobson (2003) Can. J. Neurol. Sci. 30(Suppl. 1) S2-S9
R551		Holcomb <i>et al.</i> (1982) Eur. J. Pharmacol. 82, 173-178
R552		Holman (2004) Arthritis & Rheumatism 50(Suppl. 9), S698, Abstr. 1870
R553		Holman (2004) J. Musculoskeletal Pain 12(1), 69-74
R554		Holman (2005) Arthritis & Rheumatism 52(8), 2495-2505
R555		Hornykiewicz (2002) Encyclopedia of Life Sciences Vol 13, 695-704
R556		Hundemer <i>et al.</i> (2001) Sleep 24( Abstr. Suppl.), A17, Abstr. 027.N
R557		Jackson (1989) Naunyn-Schmiedeberg's Arch. Pharmacol. 340, 355-365
R558		Jimmerson <i>et al.</i> (1976) J. Pharm. Pharmacol. 28, 845-846
R559		Johnson <i>et al.</i> (1970) Proc. Western Pharmacol. Soc. 13, 87-92
R560		Johnson <i>et al.</i> (1970) Life Science 9(1), 471-476
R561		Johnston <i>et al.</i> (2004) Current Opinion Invest. Drugs 5(7), 720-726
R562		Joyce (2001) Pharmacol. Ther. 90, 231-259
R563		Kamata (1984) Life Sciences 34, 2419-2427
R564		Keller (1980) Adv. Biochem. Psychopharmacol. 24, 175-179
R565		Kelly <i>et al.</i> (1997) Pharmacol. Ther. 74(3), 299-316
R566		Khaitan (1994) Psychopharmacol. 113, 529-542
R567		Kim <i>et al.</i> (1993) J. Pharmaceutical Sciences 82(4), 355-361
R568		Klimek <i>et al.</i> (1987) Eur. J. Pharmacol. 139(2) 163-169
R569		Klimek <i>et al.</i> (1989) J. Pharm. Pharmacol. 41(8), 455-458

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
		6102-000009/US/NP	10/565699
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT	
Sheet 7 of 9		D. Scheller <i>et al.</i>	
		FILING DATE	GROUP
		January 25, 2006	1617

### OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
R570		Knott <i>et al</i> (1990) in Bowery <i>et al.</i> , eds., "GABA <sub>A</sub> Receptors in Mammalian Function", pp 336-346
R571		Koe <i>et al.</i> (2006) Abstr. 231st ACS Nat. Meeting, Abstr. MEDI-185
R572		Koide <i>et al.</i> (1981) Life Sciences 28(10), 1139-1145
R573		Kostowski (1992) Pharmacology & Toxicology 71(1), 24-30
R574		Lee <i>et al.</i> (1982) Psychiatry Research 7, 111-119
R575		Levien (2005) Advances in Pharmacy 3(1), 62-92
R576		LeWitt (2007) Neurology 68(16), 1262-1267
R577		Linazasoro (2004) Movement Disorders 19(7), 743-754
R578		Littlejohn (2006) Current Pharm. Design 12, 3-9
R579		Liu <i>et al.</i> (1993) J. Med. Chemistry 36, 4221-4229
R580		Menon <i>et al.</i> (1972) Eur. J. Pharmacol. 19, 43-51
R581		Metman (2001) Clinical Neuropharmacol 24(3), 163-169
R582		Modigh <i>et al.</i> (1984) in Lerer <i>et al.</i> , eds. "ECT: Basic Mechanisms": John Libbey, pp 18-27
R583		Mulroney <i>et al.</i> (1994) J. Pharmacol. Exp. Ther. 288(2), 862-867
R584		Murray (1997) Lancet 349, 1498
R585		Newman-Tancredi (2002) J. Pharmacol. Exp. Ther. 303(2), 805-813
R586		Nowak <i>et al.</i> (1985) J. Neural Transmission 64, 227-238
R587		Nurse <i>et al.</i> (1984) Neurochemical Research 9(9), 1231-1238
R588		Ong <i>et al.</i> (1988) J. Pharm. Pharmacol. 40, 746-747
R589		Ono <i>et al.</i> (1984) Neuropharmacol. 23(6), 637-642
R590		Ono <i>et al.</i> (1989) J. Pharmacobiol-Dyn. 12, 384-391
R591		Ostow (2002) American J. Psychiatry 159(2), 320-321
R592		Page (2002) J. Pharmacol. Exp. Ther. 302(3), 1220-1227
R593		Park (1972) Current Therapeutic Research 14(2), 65-70
R594		Pascual (1992) Annals of Neurology 32(5), 703-707
R595		Pessoa-Mahna <i>et al.</i> (2003) Mini Reviews in Medicinal Chemistry 3(2), 77-93

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		6102-000009/US/NP	10/565699
Sheet 8 of 9		APPLICANT	D. Scheller <i>et al.</i>
		FILING DATE	GROUP
		January 25, 2006	1617

### OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
R596		Piercey <i>et al.</i> (1990) Eur. J. Pharmacol. 182, 219-226
R597		Porsolt (1979) Biomedicine 30, 139-140
R598		Pradhan <i>et al.</i> (1989) Drug Develop. Research 18, 113-118
R599		Rammsayer (1997) Int. J. Neurosci. 91, 45-55
R600		Reith (1986) Pharmacol. Biochem. & Behavior 24, 305-307
R601		Robertson (1981) Neuropharmacology 20, 1335-1336
R602		Sarges <i>et al.</i> (1973) J. Medicinal Chemistry 16(9), 1003-1011
R603		Schatzberg (2002) Human Psychopharmacol. 17, S17-S22
R604		Schelkunov (1980) J. Neurol. Transmission 47, 307-312
R605		Scriabine (2003) CNS Drug Reviews 9(4), 389-395
R606		Serra <i>et al.</i> (1981) Eur. J. Pharmacol. 72(1), 131-135
R607		Sharma (2002) Neurol. Clin. N. Am. 20, 759-778
R608		Shepperson <i>et al.</i> (1982) Eur. J. Pharmacol. 81, 627-635
R609		Sherman (1982) Pharm. Biochemistry & Behavior 16, 449
R610		Shiro <i>et al.</i> (1996) Psychiatry & Clinical Neurosciences 50, 141-146
R611		Skuza <i>et al.</i> (1989) Pol. J. Pharmacol. Pharm. 41, 421-429
R612		Sonesson (1995) J. Med. Chem. 38(8), 1319-1329
R613		Stiasny-Kolster <i>et al.</i> (2005) "Pitoligotine in the Treatment of Moderate to Severe Idiopathic Restless Legs Syndrome – a Double-Blind Placebo-Controlled Multi-Center Dose-Finding Study", presented at EFNS Conf.
R614		Stockmeier <i>et al.</i> (1992) Neuropharmacol. 31(11), 1089-1094
R615		Stockmeier <i>et al.</i> (1997) Neuropsychopharmacology 16(2), 162-173
R616		Stockmeier (1998) J. Neuroscience 18(18), 7394-7401
R617		Sumiyoshi <i>et al.</i> (1997) Neuropsychopharmacol. 16, 183-190
R618		Timmerman <i>et al.</i> (1990) Eur. J. Pharmacol. 181(3), 253-260
R619		Tuite (2003) Expert Opinion Investig. Drugs 12(8), 1335-1352
R620		van Gaalen <i>et al.</i> (2002) Genes, Brain & Behavior 1, 174-177

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
		6102-000009/US/NP	10/565699
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT	
		D. Scheller <i>et al.</i>	
Sheet 9 of 9		FILING DATE	GROUP
		January 25, 2006	1617

#### OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
R621		van Riezen <i>et al.</i> (1977) Br. J. Pharmacol. 60(4), 521
R622		Vance (1983) Research Comm. Chem. Pathology & Pharmacology 40(2), 345-348
R623		Westenberg (1999) J. Clin. Psychiatry 60 (Suppl 17)
R624		Wikstrom (1992) Progress in Medical Chemistry 29, 185-216
R625		Willner <i>et al.</i> (1988) in "Progress in Catecholamine Research, Part C, Clinical Aspects", pp 275-279
R626		Zhdanova (2004) Expert Opinion Pharmacotherapy 5(7), 1573-1579

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Examiner: /Kendra Carter/

Date Considered: 10/21/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.